Improving Long-Term Outcomes in Coronary Interventions: AGENT™ Paclitaxel-Coated Balloon Catheter

Improving Long-Term Outcomes in Coronary Interventions: AGENT™ Paclitaxel-Coated Balloon Catheter

Coronary artery disease (CAD) occurs when fatty deposits (plaque) build up in the arteries supplying blood to the heart, leading to hardening or narrowing of the vessels (atherosclerosis). This can limit oxygen-rich blood flow, causing symptoms such as chest pain, weakness, and shortness of breath.

Sometimes, arteries previously treated with a stent can become narrowed or blocked again, a condition known as in-stent restenosis (ISR) [1]. Traditional treatment involves balloon angioplasty to reopen the artery, but recurrence is common.

The AGENT™ Paclitaxel-Coated Balloon Catheter (Agent DCB) provides an innovative solution, showing an 11.1% reduction in major adverse cardiac events, including repeat procedures, at 12 months [2]. Approved by the FDA in February 2024, the Agent DCB is intended for coronary arteries 2.0–4.0 mm in diameter and lesions up to 26 mm in length, after proper vessel preparation. Preventing recurrent narrowing helps improve long-term outcomes and quality of life for patients with ISR.

The Agent DCB system is identical to the Emerge™ PTCA Balloon Catheter System, meaning that it retains all its common functionality. It is a monorail, with balloon diameters of 2-4.0mm and lengths of 12-30mm, with a dual lumen distal section for guidewire and balloon inflation. Additionally, it has radiopaque marker bands for placement and a hydrophilic coating for easier navigation. The only difference is a therapeutic paclitaxel drug coating (TransPax™) on the original Emerge catheter that does not alter the mechanical performance. TransPax™ consists of Paclitaxel (PTx), which is an active ingredient that can inhibit smooth muscle cell proliferation. The inactive ingredient is Acetyl tributyl citrate (ATBC), which allows the drug to adhere to the balloon surface and control release.

The Agent DCB system provides dual action: mechanical expansion of the artery and localized delivery of paclitaxel directly to the target site, minimizing exposure to surrounding tissue. This combined approach inhibits neointimal hyperplasia, the primary cause of in-stent restenosis following stent placement. Neointimal hyperplasia is the abnormal proliferation of smooth muscle cells within the stented artery, leading to restenosis over time [3]. The semi-compliant balloon ensures controlled expansion, reducing the risk of overstretching the vessel. Because the catheter retains the mechanical properties of the Emerge™ balloon, clinicians can use it with minimal adjustment to existing techniques.

This innovative technology allows for the potential of future innovations within the catheter space. Especially for combination therapies, it can potentially allow for improved coatings. Most importantly, it will reduce repeat procedures, decrease hospital re-admissions, and overall improve the patient's quality of life, one stent at a time.

Article written by Jennifer Joanna-Joan Villeneuve, M.ESc Biomedical Engineering Candidate, B.ESc Mechatronic Systems & B.ESc Biomedical Engineering

Image courtesy of U.S. Food & Drug Administration

Back To Medical Marketing